Q1 EPS Estimate for Coya Therapeutics Boosted by Analyst

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at HC Wainwright boosted their Q1 2026 earnings per share estimates for Coya Therapeutics in a research note issued to investors on Monday, February 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.33) for the quarter, up from their previous estimate of ($0.37). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.52) EPS.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $3.70 million. Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.

Several other equities analysts have also issued reports on COYA. BTIG Research lifted their price objective on shares of Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Lake Street Capital reaffirmed a “buy” rating and set a $17.00 target price on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $4.42 on Wednesday. The firm has a 50-day simple moving average of $5.29 and a 200-day simple moving average of $5.86. Coya Therapeutics has a one year low of $3.94 and a one year high of $8.29. The firm has a market cap of $92.47 million, a P/E ratio of -3.98 and a beta of 0.27.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. CM Management LLC boosted its holdings in Coya Therapeutics by 16.7% in the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock worth $2,030,000 after acquiring an additional 50,000 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Coya Therapeutics in the 4th quarter valued at approximately $81,000. JPMorgan Chase & Co. acquired a new stake in Coya Therapeutics in the 3rd quarter worth approximately $28,000. Lantern Wealth Advisors LLC purchased a new stake in Coya Therapeutics during the 3rd quarter worth approximately $66,000. Finally, Prosperity Wealth Management Inc. grew its position in Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after purchasing an additional 3,350 shares during the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.